Biogen Management
Management criteria checks 4/4
Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 1.5 years. total yearly compensation is $4.07M, comprised of 39.3% salary and 60.7% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $1.53M. The average tenure of the management team and the board of directors is 4 years and 4.9 years respectively.
Key information
Chris Viehbacher
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 39.3% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.005% |
| Management average tenure | 4yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
Apr 29Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Apr 28
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)
Apr 15We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings
Feb 21Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Feb 16Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
Feb 14Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Jan 31Biotech And Pharma Diversification Pays Off
Jan 25Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult
Dec 26An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued
Oct 21Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Oct 03Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?
Jul 16Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet
Jun 28An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued
Apr 14Is Biogen (NASDAQ:BIIB) A Risky Investment?
Mar 27Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)
Jan 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$4m | US$2m | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$30m | US$154k | US$3b |
Compensation vs Market: Chris's total compensation ($USD4.07M) is below average for companies of similar size in the US market ($USD13.62M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Viehbacher (62 yo)
1.5yrs
Tenure
US$4,069,913
Compensation
Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$4.07m | 0.0048% $ 1.5m | |
| Executive VP & CFO | 3.8yrs | US$7.17m | 0.013% $ 4.2m | |
| Head of Pharmaceutical Operations & Technology | 2.3yrs | US$5.71m | 0.0066% $ 2.1m | |
| Executive VP & Chief Legal Officer | 18.3yrs | US$6.70m | 0.035% $ 11.3m | |
| Head of Global Product Strategy & Commercialization | 3.3yrs | US$5.45m | 0.0067% $ 2.1m | |
| Senior VP & Chief Accounting Officer | 5.5yrs | no data | 0.0043% $ 1.4m | |
| Senior VP & Head of Investor Relations | 1.2yrs | no data | no data | |
| Chief Communication Officer & Head of Corporate Affairs | 4.3yrs | no data | no data | |
| Executive VP & Head of Corporate Development | 1.1yrs | no data | 0.00045% $ 143.4k | |
| Executive VP & Chief Human Resources Officer | 6.8yrs | US$5.08m | 0.0093% $ 3.0m | |
| President & Head of North America | 6.8yrs | no data | no data | |
| Head of Biotherapeutics & Medicinal Sciences | 6.8yrs | no data | no data |
4.0yrs
Average Tenure
57yo
Average Age
Experienced Management: BIIB's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$4.07m | 0.0048% $ 1.5m | |
| Independent Director | 14.2yrs | US$435.32k | 0.012% $ 3.9m | |
| Independent Director | 4.9yrs | US$425.73k | 0.0029% $ 918.0k | |
| Independent Chair of the Board | 14.3yrs | US$646.13k | 0.016% $ 5.1m | |
| Independent Director | 14.2yrs | US$418.02k | 0.014% $ 4.3m | |
| Independent Director | 2.9yrs | US$412.90k | 0.0015% $ 468.5k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 4.9yrs | US$433.23k | 0.0035% $ 1.1m | |
| Independent Director | less than a year | US$334.53k | 0.00032% $ 102.0k |
4.9yrs
Average Tenure
64yo
Average Age
Experienced Board: BIIB's board of directors are considered experienced (4.9 years average tenure).